AlzeCure Pharma AB of Sweden is developing small-molecule central nervous system drug candidates –that should offer big advantages over biologics, notably better permeability across the blood-brain barrier for treating of diseases of the brain, and much lower relative cost burdens for long-term treatment, its CEO told Scrip.
The Huddinge-based biotech was founded in 2016 by five scientists who had all previously worked within the CNS research area...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)